Activin E–ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Body fat distribution is a heritable risk factor for cardiovascular and metabolic disease. In humans, rare Inhibin beta E ( INHBE , activin E) loss-of-function variants are associated with a lower waist-to-hip ratio and protection from type 2 diabetes. Hepatic fatty acid sensing promotes INHBE expression during fasting and in obese individuals, yet it is unclear how the hepatokine activin E governs body shape and energy metabolism. Here, we uncover activin E as a regulator of adipose energy storage. By suppressing β-agonist-induced lipolysis, activin E promotes fat accumulation and adipocyte hypertrophy and contributes to adipose dysfunction in mice. Mechanistically, we demonstrate that activin E elicits its effect on adipose tissue through ACVR1C, activating SMAD2/3 signaling and suppressing PPARG target genes. Conversely, loss of activin E or ACVR1C in mice increases fat utilization, lowers adiposity, and drives PPARG-regulated gene signatures indicative of healthy adipose function. Our studies identify activin E–ACVR1C as a metabolic rheostat promoting liver–adipose cross talk to restrain excessive fat breakdown and preserve fat mass during prolonged fasting, a mechanism that is maladaptive in obese individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lastly, Activin E (INHBE), a liver-derived member of the TGFβ superfamily which signals through ACVR1C to activate Smad proteins, was shown to suppress adipose tissue lipolysis and result in decreased fat mass in INHBE knockout mice [31], demonstrating an adipose-specific effect of signaling via TGFβ-family ligands.”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“Differential gene expression analysis was performed using the DESeq2 package (53).”
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data
(2021) · doi:10.1016/j.xinn.2021.100141 · Cited by 12,455 · cited 1×
“Pathway enrichment analysis was performed using the clusterProfiler package (55).”
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
General and abdominal adiposity and risk of death in Europe
Pischon, T., Boeing, H., Hoffmann, K., Bergmann, M., Schulze, M. B., Overvad, K., van der Schouw, Y. T., Spencer, E., Moons, K. G. M., Tjønneland, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801891 · Cited by 2,155
Insulin action and resistance in obesity and type 2 diabetes
Czech, M. P. (2017) · Nature Medicine · doi:10.1038/nm.4350 · Cited by 1,258
The Emerging Risk Factors Collaboration (2011) · The Lancet · doi:10.1016/s0140-6736(11)60105-0 · Cited by 1,216 · cited 5×
“Inhbe deletion in mice results in net fat loss and body weight reduction, whereas humans with heterozygous INHBE pLOF display higher BMI and enlarged gluteofemoral (subcutaneous) adipose tissue (11), similar to the effects of PPARG agonists (28).”
InfluentialEctopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
Shulman, G. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1011035 · Cited by 1,126 · cited 1×
“Hepatic lipid content is associated with systemic insulin sensitivity (30).”
False discovery rates: a new deal
Stephens, M. (2016) · Biostatistics · doi:10.1093/biostatistics/kxw041 · Cited by 1,067
Why does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
Lipolysis: cellular mechanisms for lipid mobilization from fat stores
Grabner, G. F., Xie, H., Schweiger, M., & Zechner, R. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00493-6 · Cited by 765
Tansey, J. T., Sztalryd, C., Gruia-Gray, J., Roush, D. L., Zee, J. V., Gavrilova, O., Reitman, M. L., Deng, C.-X., Li, C., Kimmel, A. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101042998 · Cited by 734 · cited 1×
“Similar discrepancies are seen for PLIN1 pLOF in humans and mice (11, 41, 42).”
EPIC-InterAct Consortium, Lotta, L. A., Cambridge FPLD1 Consortium, Gulati, P., Day, F. R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K. J., Eicher, J. D., et al. (2017) · Nature Genetics · doi:10.1038/ng.3714 · Cited by 585 · cited 1×
“…studies examining the impact of the waist- to-hip circumference ratio (WHR), a surrogate for abdominal versus gluteofemoral adiposity, on cardiometabolic disease and mortality revealed that body fat distribution plays a major role in determining disease risk independently of total fat mass (4–8).”
Self-citationHigh-throughput engineering of the mouse genome coupled with high-resolution expression analysis
Valenzuela, D. M., Murphy, A. J., Frendewey, D., Gale, N. W., Economides, A. N., Auerbach, W., Poueymirou, W. T., Adams, N. C., Rojas, J., Yasenchak, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt822 · Cited by 584 · cited 1×
“The genetically engineered Inhbe −/− (MAID 6634) and Acvr1c −/− (MAID 981) mouse strains were created using Regeneron’s VelociGene® technology (50, 51).”
Self-citationEmdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Zekavat, S. M., Hsiao, A. J., & Kathiresan, S. (2017) · JAMA · doi:10.1001/jama.2016.21042 · Cited by 378
Dale, C. E., Fatemifar, G., Palmer, T. M., White, J., Prieto-Merino, D., Zabaneh, D., Engmann, J. E. L., Shah, T., Wong, A., Warren, H. R., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026560 · Cited by 345
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338
Activins and Inhibins: Roles in Development, Physiology, and Disease
Namwanje, M., & Brown, C. W. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021881 · Cited by 294
Regulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273 · cited 2×
“While several activin/TGF β ligands are known to engage ACVR1C, the phenotypes of mice lacking these ligands do not support their roles in modulating fat distribution through ACVR1C (18, 24–27).”
PPARadigms and PPARadoxes: expanding roles for PPARγ in the control of lipid metabolism
Walczak, R., & Tontonoz, P. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30159-0 · Cited by 270
Demetrius, L. (2005) · The EMBO Reports · doi:10.1038/sj.embor.7400422 · Cited by 257
Poueymirou, W. T., Auerbach, W., Frendewey, D., Hickey, J. F., Escaravage, J. M., Esau, L., Doré, A. T., Stevens, S., Adams, N. C., Dominguez, M. G., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1263 · Cited by 238 · cited 2×
“The genetically engineered Inhbe −/− (MAID 6634) and Acvr1c −/− (MAID 981) mouse strains were created using Regeneron’s VelociGene® technology (50, 51).”
Self-citationLotta, L. A., Wittemans, L. B. L., Zuber, V., Stewart, I. D., Sharp, S. J., Luan, J., Day, F. R., Li, C., Bowker, N., Cai, L., et al. (2018) · JAMA · doi:10.1001/jama.2018.19329 · Cited by 229
Self-citationThe InterAct Consortium (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001230 · Cited by 216 · cited 1×
“A larger WHR or waist circumference is strongly associated with higher incidence of cardiovascular disease and type 2 diabetes, while a lower WHR is protective against these disorders, even in individuals with a high BMI (9, 10).”
Gusarova, V., Alexa, C. A., Wang, Y., Rafique, A., Kim, J. H., Buckler, D., Mintah, I. J., Shihanian, L. M., Cohen, J. C., Hobbs, H. H., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054890 · Cited by 210 · cited 1×
“Triglyceride content was measured using Infinity Triglycerides reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions and normalized to wet tissue weight, as previously described (52).”
Self-citationPPARγ regulates adipose triglyceride lipase in adipocytes in vitro and in vivo
Kershaw, E. E., Schupp, M., Guan, H.-P., Gardner, N. P., Lazar, M. A., & Flier, J. S. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00122.2007 · Cited by 209
Elevated expression of activins promotes muscle wasting and cachexia
Chen, J. L., Walton, K. L., Winbanks, C. E., Murphy, K. T., Thomson, R. E., Makanji, Y., Qian, H., Lynch, G. S., Harrison, C. A., & Gregorevic, P. (2014) · The FASEB Journal · doi:10.1096/fj.13-245894 · Cited by 202 · cited 1×
“S5 C ) (33, 34).”
Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B–null mice
Choi, Y. H., Park, S., Hockman, S., Zmuda-Trzebiatowska, E., Svennelid, F., Haluzik, M., Gavrilova, O., Ahmad, F., Pepin, L., Napolitano, M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24867 · Cited by 180 · cited 1×
“Pde3b - deficient mice have lower fat mass due to enhanced lipolysis but exhibit insulin resistance and hepatic steatosis, akin to Inhbe KOs (40).”
Mest/Peg1 imprinted gene enlarges adipocytes and is a marker of adipocyte size
Takahashi, M., Kamei, Y., & Ezaki, O. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00244.2004 · Cited by 170 · cited 1×
“Besides metabolic genes, elevated activin E induced markers of adipocyte hypertrophy (e.g., Mest, Sfrp5 ) (31, 32) and inflammation (e.g., Itgax, Saa3 ) (Fig.”
Andersson, O., Korach-Andre, M., Reissmann, E., Ibáñez, C. F., & Bertolino, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800272105 · Cited by 126 · cited 1×
“In contrast, Gdf3 −/− mice are resistant to diet-induced obesity and display normal insulinemia and glucose control (26).”
Activin βC and βE Genes Are Not Essential for Mouse Liver Growth, Differentiation, and Regeneration
Lau, A. L., Kumar, T. R., Nishimori, K., Bonadio, J., & Matzuk, M. M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.6127-6137.2000 · Cited by 124 · cited 4×
“While several activin/TGF β ligands are known to engage ACVR1C, the phenotypes of mice lacking these ligands do not support their roles in modulating fat distribution through ACVR1C (18, 24–27).”
InfluentialATGL-dependent white adipose tissue lipolysis controls hepatocyte PPARα activity
Fougerat, A., Schoiswohl, G., Polizzi, A., Régnier, M., Wagner, C., Smati, S., Fougeray, T., Lippi, Y., Lasserre, F., Raho, I., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110910 · Cited by 111
The activin axis in liver biology and disease
Rodgarkia‐Dara, C., Vejda, S., Erlach, N., Losert, A., Bursch, W., Berger, W., Schulte‐Hermann, R., & Grusch, M. (2006) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2006.07.002 · Cited by 110 · cited 1×
“Accordingly, INHBE is up-regulated during fasting and permanently increased in obese individuals with insulin resistance or NASH (11, 14–16), in which elevated basal lipolysis or hepatic lipogenesis increases liver fatty acid levels.”
Mouse models of inherited lipodystrophy
Savage, D. B. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.002907 · Cited by 105
Activin B receptor ALK7 is a negative regulator of pancreatic β-cell function
Bertolino, P., Holmberg, R., Reissmann, E., Andersson, O., Berggren, P.-O., & Ibáñez, C. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801285105 · Cited by 91 · cited 2×
“While several activin/TGF β ligands are known to engage ACVR1C, the phenotypes of mice lacking these ligands do not support their roles in modulating fat distribution through ACVR1C (18, 24–27).”
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88 · cited 1×
“Blockade of activin receptor type IIB (ActRIIB) in mice similarly causes rapid glucose intolerance, while it improves glycemic control in humans (37–39).”
Adipocyte ALK7 links nutrient overload to catecholamine resistance in obesity
Guo, T., Marmol, P., Moliner, A., Björnholm, M., Zhang, C., Shokat, K. M., & Ibanez, C. F. (2014) · eLife · doi:10.7554/elife.03245 · Cited by 81 · cited 2×
“…of ACVR1C: Genetic or pharmacological inhibition in mice results in profound fat loss via lipolysis, yet causes hepatic steatosis and severe insulin resistance (21, 22, 24, 35, 36) Inhbb −/− mutants show no signs of insulin resistance or hepatic steatosis and have no changes in fat mass (24, 25).”
Activin E controls energy homeostasis in both Brown and white adipose tissues as a hepatokine
Hashimoto, O., Funaba, M., Sekiyama, K., Doi, S., Shindo, D., Satoh, R., Itoi, H., Oiwa, H., Morita, M., Suzuki, C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.008 · Cited by 77 · cited 4×
“…OE of activin E in adult mice produced remarkably beneficial effects on glycemic control, consistent with the data from activin E transgenic mice (19) but suggesting a major discrepancy between humans and mice: With regard to diabetes, INHBE loss- of-function is protective in humans (11, 12),…”
InfluentialYogosawa, S., Mizutani, S., Ogawa, Y., & Izumi, T. (2013) · Diabetes · doi:10.2337/db12-0295 · Cited by 72 · cited 1×
“ACVR1C enables canonical activin-SMAD2/3 signaling, resulting in SMAD-mediated transcriptional suppression of Pparg and Cebpa , and subsequent blockade of adipose lipolysis (21–23).”
Rodriguez-Cuenca, S., Carobbio, S., Velagapudi, V. R., Barbarroja, N., Moreno-Navarrete, J. M., Tinahones, F. J., Fernandez-Real, J. M., Orešič, M., & Vidal-Puig, A. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06154-11 · Cited by 67 · cited 1×
“While PPARG controls genes related to both fasting-induced lipid mobilization and postprandial nutrient uptake and storage (46–48), we hypothesize that a key difference between humans and mice may be the relative balance between these opposing processes.”
Akbari, P., Sosina, O. A., Bovijn, J., Landheer, K., Nielsen, J. B., Kim, M., Aykul, S., De, T., Haas, M. E., Hindy, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32398-7 · Cited by 66 · cited 9×
“Recent studies suggest that Inhbe (activin E) expression is increased in humans with NASH and insulin resistance (11, 14), as well as in obese mice upon high fat feeding ( SI Appendix , Fig.”
InfluentialSelf-citationMouse models of PPAR-γ deficiency: dissecting PPAR-γ's role in metabolic homoeostasis
Gray, S. L., Dalla Nora, E., & Vidal-Puig, A. J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331053 · Cited by 63
Rosiglitazone, PPARγ, and Type 2 Diabetes
Kahn, B. B., & McGraw, T. E. (2010) · New England Journal of Medicine · doi:10.1056/nejmcibr1012075 · Cited by 59
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity
Deaton, A. M., Dubey, A., Ward, L. D., Dornbos, P., Flannick, J., AMP-T2D-GENES Consortium, Yee, E., Ticau, S., Noetzli, L., Parker, M. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31757-8 · Cited by 57 · cited 8×
“Yet, human PDE3B pLOF is associated with beneficial fat distribution and protection from type 2 diabetes (11, 12).”
InfluentialSugiyama, M., Kikuchi, A., Misu, H., Igawa, H., Ashihara, M., Kushima, Y., Honda, K., Suzuki, Y., Kawabe, Y., Kaneko, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194798 · Cited by 52 · cited 4×
“Accordingly, INHBE is up-regulated during fasting and permanently increased in obese individuals with insulin resistance or NASH (11, 14–16), in which elevated basal lipolysis or hepatic lipogenesis increases liver fatty acid levels.”
InfluentialEmdin, C. A., Khera, A. V., Aragam, K., Haas, M., Chaffin, M., Klarin, D., Natarajan, P., Bick, A., Zekavat, S. M., Nomura, A., et al. (2019) · Diabetes · doi:10.2337/db18-0857 · Cited by 42 · cited 1×
“Human genetic analyses provided some hints to unravel these questions. pLOF variants in ACVR1C , an activin receptor enriched in WAT, have similarly strong associations with fat distribution as INHBE (11, 12, 20).”
Bartholin, L., Maguer‐Satta, V., Hayette, S., Martel, S., Gadoux, M., Bertrand, S., Corbo, L., Lamadon, C., Morera, A.-M., Magaud, J., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204720 · Cited by 42 · cited 1×
“S5 C ) (33, 34).”
Identification of Rare Loss-of-Function Genetic Variation Regulating Body Fat Distribution
Koprulu, M., Zhao, Y., Wheeler, E., Dong, L., Rocha, N., Li, C., Griffin, J. D., Patel, S., de Streek, M. V., Glastonbury, C. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab877 · Cited by 36 · cited 1×
“Whether lipolysis plays a significant role in the regulation of human body fat distribution is currently unclear, but the enrichment of lipolysis-related genes in pLOF variants associated with WHR suggests a potential role for this pathway (11, 49).”
Self-citationHashimoto, O., Sekiyama, K., Matsuo, T., & Hasegawa, Y. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.08.007 · Cited by 29
Regulation of metabolic homeostasis by the TGF‐β superfamily receptor ALK7
Ibáñez, C. F. (2021) · FEBS Journal · doi:10.1111/febs.16090 · Cited by 29
Targeting activin receptor–like kinase 7 ameliorates adiposity and associated metabolic disorders
Zhao, M., Okunishi, K., Bu, Y., Kikuchi, O., Wang, H., Kitamura, T., & Izumi, T. (2023) · JCI Insight · doi:10.1172/jci.insight.161229 · Cited by 28 · cited 1×
“…of ACVR1C: Genetic or pharmacological inhibition in mice results in profound fat loss via lipolysis, yet causes hepatic steatosis and severe insulin resistance (21, 22, 24, 35, 36) Inhbb −/− mutants show no signs of insulin resistance or hepatic steatosis and have no changes in fat mass (24, 25).”
A Soluble Activin Receptor Type IIB Does Not Improve Blood Glucose in Streptozotocin-Treated Mice
Wang, Q., Guo, T., Portas, J., & McPherron, A. C. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10430 · Cited by 25 · cited 1×
“Blockade of activin receptor type IIB (ActRIIB) in mice similarly causes rapid glucose intolerance, while it improves glycemic control in humans (37–39).”
Bonomi, L. M., Brown, M., Ungerleider, N., Muse, M. E., Matzuk, M. M., & Schneyer, A. L. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00177.2012 · Cited by 25 · cited 1×
“…of ACVR1C: Genetic or pharmacological inhibition in mice results in profound fat loss via lipolysis, yet causes hepatic steatosis and severe insulin resistance (21, 22, 24, 35, 36) Inhbb −/− mutants show no signs of insulin resistance or hepatic steatosis and have no changes in fat mass (24, 25).”
Anunciado‐Koza, R. P., Higgins, D., & Koza, R. A. (2015) · Biochimie · doi:10.1016/j.biochi.2015.05.007 · Cited by 22 · cited 1×
“Besides metabolic genes, elevated activin E induced markers of adipocyte hypertrophy (e.g., Mest, Sfrp5 ) (31, 32) and inflammation (e.g., Itgax, Saa3 ) (Fig.”
Spontaneous development of hepatosteatosis in perilipin-1 null mice with adipose tissue dysfunction
Wei, S., Liu, S., Su, X., Wang, W., Li, F., Deng, J., Lyu, Y., Geng, B., & Xu, G. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.11.007 · Cited by 17 · cited 1×
“Similar discrepancies are seen for PLIN1 pLOF in humans and mice (11, 41, 42).”
Srivastava, R. K., Lee, E. S., Sim, E. W., Sheng, N. C., & Ibáñez, C. F. (2021) · The FASEB Journal · doi:10.1096/fj.202002785rr · Cited by 11 · cited 1×
“…of ACVR1C: Genetic or pharmacological inhibition in mice results in profound fat loss via lipolysis, yet causes hepatic steatosis and severe insulin resistance (21, 22, 24, 35, 36) Inhbb −/− mutants show no signs of insulin resistance or hepatic steatosis and have no changes in fat mass (24, 25).”
Research works printed but not linked: 1
- R. C. Adam, Transcriptome analysis of adipose tissue of Inhbe knockout and over-expressing mice. NCBI Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE231444. Deposited 1 May 2023.
Cited by
Nunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., Calhoun, R., Lee, M., Holman, C. D., Baur, J. A., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101880 · Cited by 126
Adipose tissue lipid metabolism: lipolysis
Cho, C. H., Patel, S., & Rajbhandari, P. (2023) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2023.102114 · Cited by 109
Xia, Y., Jin, J., Sun, Y., Kong, X., Shen, Z., Yan, R., Huang, R., Liu, X., Xia, W., Ma, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113499 · Cited by 76
Mastaitis, J. W., Gomez, D., Raya, J. G., Li, D., Min, S., Stec, M., Kleiner, S., McWilliams, T., Altarejos, J. Y., Murphy, A. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59485-9 · Cited by 53
Self-citationGriffin, J. D., Buxton, J. M., Culver, J. A., Barnes, R., Jordan, E. A., White, A. R., Flaherty, S. E., Bernardo, B. L., Ross, T. T., Bence, K. K., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101830 · Cited by 41
“While this manuscript was in preparation, Adam et al. reported that adenovirus mediated Activin E overexpression in mice reduced fasting NEFA in an ALK7 dependent manner [47].”
Method
Metadata
- Authors
- Adam, R. C., Pryce, D. S., Lee, J. S., Zhao, Y., Mintah, I. J., Min, S., Halasz, G., Mastaitis, J., Atwal, G. S., Aykul, S., Idone, V., Economides, A. N., Lotta, L. A., Murphy, A. J., Yancopoulos, G. D., Sleeman, M. W., & Gusarova, V.
- Affiliations
- Regeneron (United States) (US)
- Regeneron Pharmaceuticals, Tarrytown, NY 10591
- Corresponding author
- Yancopoulos, George D.
- Gusarova, Viktoria
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2023-07-31
- Volume
- 120
- Issue
- 32
- Pages
- e2309967120-e2309967120
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC10410708
- OpenAlex
- W4385409675
- Cited by
- 44
- References
- 55
- Citations by year
- 2026: 16 · 2025: 13 · 2024: 12 · 2023: 3
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- adipose tissue lipolysis, adipocyte hypertrophy, adipose tissue dysfunction, Smad2/3 signaling, energy metabolism, fasting, obesity, body fat distribution, hepatokines
- MeSH terms
- Adipose Tissue, Animals, Diabetes Mellitus, Type 2, Humans, Lipolysis, Obesity, Activins, Activin Receptors, Type I, PPAR gamma, Adiposity, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.